Pulse Biosciences Presents Late-Breaking Data from nPulse™ Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium
Published: 13 Mar 2026
Author: Precedence Research
Pulse Biosciences, a company leveraging technology using its proprietary Nanosecond Pulsed Field Ablation, announced that late-breaking data from the nPulse Cardiac Catheter Ablation System first-in-human feasibility study in Europe. This data will be presented by MD, Director of Cardiac Arrhythmia Services at the Mount Sinai Fuster Heart Hospital, NY, Vivek Reddy include 6-month and 12-month follow-up data from the nPulse Cardiac Catheter Ablation System first-in-human feasibility study conducted in Europe.
The data were presented at the 2026 AF symposiumin Boston, USA. The feasibility study included a 100% rate of procedural success in 75 evaluable patients at six months and a 96% rate of procedural success across 47 evaluable patients at one year. The average number of applications was 16.1 per procedure, while total procedure and fluoroscopy times were 65 and 9.8 minutes, respectively, and left atrial dwell time was 21 minutes.
About Pulse Biosciences
The Company is actively pursuing the development of its nPulse technology for use in the treatment of atrial fibrillation and in a few other few market it showed a positive impact on both patients and providers. Registered trademarks of Pulse Biosciences, Inc. in the United Statesare Pulse Biosciences, nPulse, Vybrance, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, and CellFX nsPFA.
According to Toward Healthcare, the Cardiac Cannula market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 288.78 million in 2026 to approximately USD 510.71 million by 2035, representing a compound annual growth rate (CAGR) of 6.54% from 2026 to 2035. This market catheter design, differentiated energy, and zero rotation workflow have produced highly efficient and effective results when compared to other AF feasibility studies in my experience, highlighting the nPulse cardiac catheter’s simple and effective workflow for PVI.”
Forward-Looking Statements
Statements concerning early clinical successes and whether they are predictive of the safety and effectiveness of any medical device, such as the nPulse Cardiac Catheter, Pulse Biosciences, whether stated or implied, will become either a disruptive treatment option or a superior option for treating atrial fibrillation or any other medical condition. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expects,” “intends,” “plans,” “projects,” “believes,”are used to identify these forward-looking statements, although not all forward-looking statements contain these words.
A recent report by Toward Healthcare highlights that the Cardiac Cannula marketis experiencing results that validate the safety, effectiveness, lesion quality, and speed benefits that clearly differentiate the nPulse cardiac catheter ablation system as a first-in-class system showing the potential to be best in class.